Transabdominal antepartum amnioinfusion.

Area of Science:

• Maternal-Fetal Medicine
• Obstetrics
• Perinatal Care

Background:

• Oligohydramnios, a condition of low amniotic fluid, poses risks to pregnancy.
• Transabdominal antepartum amnioinfusion is a procedure to increase amniotic fluid volume.
• Evaluating maternal complications associated with amnioinfusion is crucial for clinical decision-making.

Purpose of the Study:

• To assess the association between transabdominal antepartum amnioinfusion and maternal complications.
• To compare outcomes in pregnant women undergoing amnioinfusion versus conservative management for oligohydramnios.

Main Methods:

• A cohort study comparing 53 women undergoing transabdominal antepartum amnioinfusion (16-34 weeks' gestation) with 42 women receiving conservative treatment for oligohydramnios.
• Patients were divided into groups based on ruptured and unruptured membranes.
• Maternal adverse events and delivery outcomes were analyzed.

Main Results:

• Amnioinfusion was associated with a more favorable latency period between admission and delivery in both ruptured (22 vs. 11 days) and unruptured membrane groups (30 vs. 9 days).
• No significant increase in maternal adverse events was observed in the amnioinfusion group.
• Fever (maternal temperature >38°C) was less frequent in amnioinfused patients with ruptured membranes (4% vs. 23%).
• Cesarean sections for fetal distress were less frequent in the amnioinfusion group with unruptured membranes (11% vs. 50%).

Conclusions:

• Transabdominal antepartum amnioinfusion does not increase maternal complications compared to conservative treatment for oligohydramnios.
• The procedure appears to offer benefits, including potentially reducing maternal fever and the need for cesarean delivery due to fetal distress.